Brookfield Asset Management Inc. United Therapeutics Corp Transaction History

Brookfield Asset Management Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$205.95 - $280.43 $142,311 - $193,777	691 Added 2.48%	28,525 $7.93 Million
Q3 2022 Nov 14, 2022	SELL	$203.3 - $244.17 $1.08 Million - $1.29 Million	-5,293 Reduced 15.98%	27,834 $5.83 Million
Q2 2022 Nov 16, 2022	BUY	$174.81 - $241.14 $925,269 - $1.28 Million	5,293 Added 19.02%	33,127 $7.81 Million
Q2 2022 Aug 15, 2022	BUY	$174.81 - $241.14 $4.61 Million - $6.36 Million	26,361 Added 389.61%	33,127 $7.81 Million
Q1 2022 May 16, 2022	SELL	$166.16 - $213.96 $345,446 - $444,822	-2,079 Reduced 23.5%	6,766 $1.21 Million
Q4 2021 Feb 14, 2022	BUY	$184.32 - $216.08 $1.63 Million - $1.91 Million	8,845 New	8,845 $1.91 Million

672

42.4M

194K

295K

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $16.5B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

Get notified when there are updates to the investment portfolio of Brookfield Asset Management Inc., based on Form 13F filings with the SEC.

Stay updated on Brookfield Asset Management Inc. with notifications on news.